
July 2 (Reuters) - Instil Bio Inc TIL.O:
INSTIL BIO ANNOUNCES U.S. F.D.A. CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR AXN-2510, A PD-L1XVEGF BISPECIFIC ANTIBODY, FOR A PHASE 1 TRIAL IN RELAPSED/REFRACTORY SOLID TUMORS
INSTIL BIO INC - TO INITIATE PHASE 1 TRIAL OF '2510 BEFORE END OF 2025
INSTIL BIO INC - INITIAL SAFETY AND EFFICACY RESULTS FROM PHASE 2 STUDY EXPECTED IN H2 2025